Agios CSO to depart amid layoffs as biotech looks for new drugs to license or acquire - Endpoints News

A year and a half after ending work in oncology and three months after securing the first nod for its new “anchor product,” Agios is once again shaking things up. As many as 50 exploratory research employees will be let go and chief scientific officer Bruce C…

A year and a half af­ter end­ing work in on­col­o­gy and three months af­ter se­cur­ing the first nod for its new “an­chor prod­uct,” Agios is once again shak­ing things up. As many as 50 ex­plorato… [+3599 chars]

full article...